share_log

卫信康(603676.SH):子公司获得门冬氨酸钾镁注射液药品注册证书

Tibet Weixinkang Pharmaceutical (603676.SH): Subsidiary obtains registration certificate for aspartate potassium and magnesium injection.

Gelonghui Finance ·  Jun 3 05:43

On June 3rd, Gelonhui announced that Tibet Weixinkang Pharmaceutical (603676.SH) has received the Drug Registration Certificate issued by the State Food and Drug Administration for Magnesium Potassium Aspartate injection. Magnesium Potassium Aspartate injection is an electrolyte supplement drug used for hypokalemia, ventricular arrhythmias caused by digitalis poisoning, sequelae of myocarditis, congestive heart failure, and as an adjuvant therapy for myocardial infarction.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment